Lawsuit Filed for Investors in Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) – Contact Shareholders Foundation

Investors in Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) are facing a legal battle as a lawsuit has been filed against the company for alleged securities laws violations. The lawsuit, filed by an investor on July 2, 2024, claims that Bolt Biotherapeutics misrepresented the effectiveness of its product BDC-1001, leading to false and misleading statements to investors. As a result, the company is now at risk of disruptive leadership transitions and substantial workforce reduction.

Investors who purchased shares of NASDAQ: BOLT are urged to contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554. The deadline for certain investors is September 3, 2024, so time is of the essence for those affected.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and settlement claim filing service that provides information on shareholder issues, securities class actions, settlements, judgments, and other legal news related to the stock market. While not a law firm, the Shareholders Foundation aims to inform and assist investors in navigating legal challenges in the financial market.

For more information on this lawsuit and how it may impact investors in Bolt Biotherapeutics, Inc., contact the Shareholders Foundation, Inc. at mail@shareholdersfoundation.com or +1(858) 779 – 1554. Stay informed and protect your investments in the ever-changing world of the stock market.